Price Analysis of Systemic Antibacterial Drugs Approved in the US (January 1980 - December 2020)
Author(s)
Alqahtani S1, Meraya A2
1King Khalid University, Abha, 14, Saudi Arabia, 2Jazan University, Jazan, Jazan, Saudi Arabia
Presentation Documents
OBJECTIVES:
To assess price trends of systemic antibacterial drugs at the market entry in the US in the period 1980-2016, and to assess the impact of the Generating Antibiotics Incentives Now (GAIN) Act of 2012 on the prices of systemic antibacterial drugs in the US.METHODS:
Information about systemic antibacterial drugs approved by the FDA were collected from the Orange Book and FDA websites. Daily doses and duration of the treatments were extracted from the FDA-approved label, the Physician’s Desk Reference (PDR) and the Micromedex electronic webpage. Price data were extracted from the RedBook. Prices were adjusted by the consumer price index to 2016 dollars. Descriptive analysis was done. Segmented Linear Regression (SLR) was done to assess the impact of GAIN Act of 2012 on the prices of systemic antibiotics.RESULTS:
The FDA approved 70 systemic antibacterial drugs for the treatment and/or prevention of bacterial infections. Among the 70 drugs approved, 51 (72.9%) drugs had price data and were included in the analysis. When a drug indication had several possible strengths or posologies, we used the adjusted median/per course of drug therapy to estimate the minimum and maximum price per course of therapy. Our results showed that the prices of new systemic antibacterial drugs at market entry increased significantly during the period 1980-2015. The median cost per course of drug therapy was $59.3 in the period 1980-1984, $83.2 in 1985-1989, $113.0 in 1990-1995, $1572.4 in 1996-1999, $3233.9 in 2000-2004, $840.1 in 2005-2009, $14132.1 in 2010-2015CONCLUSIONS:
The prices of systemic antibacterials at market entry increased during the study period. The enactment of the GAIN Act of 2012 was associated with a significant increase in the prices of new systemic antibiotic drugs. The cost of a course of drug therapy at market entry varied by drug, indication and population subgroup.Conference/Value in Health Info
2024-11, ISPOR Europe 2024, Barcelona, Spain
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
HPR92
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes, Public Spending & National Health Expenditures
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)